P185
Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.The Joint External Evaluation of Taiwan: The External Evaluators' Perspective.Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US surveyLong-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke.Treatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingHealth care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US.Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany.Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis.Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.Federal Funding for Health Security in FY2018.Global Catastrophic Biological Risks: Toward a Working Definition.A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population.Frequency of Risk-Related News Media Messages in 2016 Coverage of Zika Virus.Impact of etanercept on work and activity impairment in employed moderate to severe rheumatoid arthritis patients in the United States.Federal Funding for Health Security in FY2019Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferonFactors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database studyDosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationTreatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sampleA cross-sectional analysis of cardiovascular disease in the hemophilia populationVector control in Zika-affected communities: Local views on community engagement and public health ethics during outbreaksTreatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeksClade X: A Pandemic ExerciseRisk-Based Decision Making During Public Health Emergencies Involving Environmental Contamination
P50
Q30670499-B128B02A-AF88-4DF0-86C3-697D2B4FD1DCQ33600893-B97EBB25-94B5-4FC2-A9B7-B341A36230ACQ33719214-F7BD3C59-6707-4002-86E3-FE286178E06BQ33825885-95827D5A-7A9B-48EC-8C58-F5F4C46242F1Q34083223-231D0867-BFD5-4FEB-A2A9-6319635F9D46Q35884067-CAA5209A-2A13-4BF1-80C4-175CF20FFB2BQ36627514-597BC3EF-6C27-44FC-8468-5C3C5F50032EQ37221862-9C8812E3-6BA3-4D61-971F-2055B3824322Q37412487-E6BC2CA3-514F-4EBF-B7C0-99A448769823Q37626336-F1191042-D857-4AE6-97C7-90386760E379Q37748763-11DC59D7-9818-433C-84D7-749D5E3E327DQ37992954-5DD96A09-EABD-4930-8BB9-11393CBA0776Q38034134-B8FCC56C-6D7B-47CF-ABFC-E9B03EC23B86Q38035726-BE7CD950-1074-42BC-8A16-809FBD1BE1D1Q40156457-162D2B54-95ED-4C0C-A581-D8923C674E59Q41557318-222A5C7B-F881-48BB-95E3-FF8DA1AC56B5Q42252182-FB97491D-821B-41B0-A7AA-B1439299A065Q43794214-4E64483B-E5EE-4D76-A10A-4959F365CB19Q43952293-BCABA46D-8A3D-412C-AB38-A083B48716F7Q45805086-1ED55CB5-B306-4E66-978B-B7D78FD072D3Q47191020-7B685B6D-0C63-4677-926D-F46DD15210B4Q51211155-53FC2F24-035E-4E85-92FE-683B5E923346Q58558312-56621324-6D5D-40B1-9E80-B93D59B842F3Q59125930-E080E7CB-B3AC-4762-BD89-DCA721B4AC48Q83345167-F3FA5F7E-8987-4C50-81D5-5FCEFC18EBADQ86378278-7FCD9DF6-3DCC-4366-993D-BB64291FA5CEQ87412497-F7A0C932-6023-4AA7-96C4-79921B963128Q89081067-6768672B-2742-416E-A648-EBEC86FBC1CEQ90179085-7DBED069-3B4D-4B65-A97C-DDAA54454BDCQ90528742-83D4EADA-223C-4165-A43C-F027F3CDA480Q90589436-B31F611E-6F36-4FD4-80A5-DDFA2FA89B59Q91404927-3af31a36-4fa4-6057-59ab-6820b2890aad
P50
description
American coronavirus researcher
@en
name
Crystal Watson
@en
type
label
Crystal Watson
@en
altLabel
Crystal R Boddie
@en
Crystal R. Watson
@en
prefLabel
Crystal Watson
@en
P1026
P184
P19
P2002
C_R_Watson
P21
P31
P496
0000-0002-3808-986X
P5008
P569
1983-04-09T00:00:00Z